Suppr超能文献

参芪复方通过调节肠道微生物群和代谢物改善 2 型糖尿病。

Shenqi compound ameliorates type-2 diabetes mellitus by modulating the gut microbiota and metabolites.

机构信息

TCM Regulating Metabolic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.

Department of Traditional Chinese Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.

出版信息

J Chromatogr B Analyt Technol Biomed Life Sci. 2022 Apr 1;1194:123189. doi: 10.1016/j.jchromb.2022.123189. Epub 2022 Feb 24.

Abstract

The gut microbiota (GM) and metabolites are important factors in mediating the development of type-2 diabetes mellitus (T2DM). An imbalance in the gut microbiota and metabolites can disrupt the function of the intestinal barrier, cause changes in the permeability of the intestinal mucosa and promote the immune inflammatory response, thereby aggravating the fluctuation of blood glucose level and promoting the occurrence and development of the chronic complications of DM. Manipulating the GM and metabolites is a promising therapeutic intervention and is being studied extensively. Shenqi compound (SQC) is a traditional Chinese medicine formulation, which has been widely used to improve T2DM. Studies have demonstrated that SQC can reduce glycemic variability, alleviate the inflammatory response, etc. However, its underlying mechanism remains unknown. Therefore, in this experiment, We administered SQC to Goto-Kakizaki (GK) rats and evaluated its effect on blood glucose homeostasis and the intestinal mucosal barrier. We identified the profiles of the GM and metabolites with the aid of 16S rDNA gene sequencing and non-target metabolomics analysis. It showed that SQC intervention could reduce glycemic variability, regulate serum levels of glucagon and insulin, and improve injury to the intestinal mucosal barrier of GK rats. In the gut, the ratio of bacteria of the phyla Bacteroidetes/Firmicutes could be improved after SQC intervention. SQC also regulated the relative abundance of Prevotellaceae, Butyricimonas, Bacteroides, Blautia, Roseburia, Lactobacillus, and Rothia. We found out that expression of 40 metabolites was significantly improved after SQC intervention. Further analyses of metabolic pathways indicated that the therapeutic effect of SQC might be related predominantly to its ability to improve gluconeogenesis/glycolysis, amino acid metabolism, lipid metabolism, citrate cycle, and butanoate metabolism. These results suggest that SQC may exert a beneficial role in T2DM by modulating the GM and metabolites in different pathways.

摘要

肠道微生物群(GM)和代谢物是介导 2 型糖尿病(T2DM)发展的重要因素。GM 和代谢物的失衡会破坏肠道屏障的功能,导致肠黏膜通透性的变化,并促进免疫炎症反应,从而加剧血糖水平的波动,促进 DM 的慢性并发症的发生和发展。操纵 GM 和代谢物是一种很有前途的治疗干预措施,目前正在广泛研究。参芪复方(SQC)是一种中药制剂,已广泛用于改善 T2DM。研究表明,SQC 可以降低血糖变异性,减轻炎症反应等。然而,其潜在机制尚不清楚。因此,在本实验中,我们给予 GK 大鼠 SQC 并评估其对血糖稳态和肠道黏膜屏障的影响。我们借助 16S rDNA 基因测序和非靶向代谢组学分析来鉴定 GM 和代谢物的特征。结果表明,SQC 干预可降低血糖变异性,调节血清胰高血糖素和胰岛素水平,并改善 GK 大鼠的肠道黏膜屏障损伤。在肠道中,SQC 干预后厚壁菌门/拟杆菌门的细菌比例可以得到改善。SQC 还调节了普雷沃氏菌科、丁酸单胞菌、拟杆菌、布劳特氏菌、罗斯伯里氏菌、乳杆菌和罗特氏菌的相对丰度。我们发现 SQC 干预后 40 种代谢物的表达显著改善。进一步的代谢途径分析表明,SQC 的治疗作用可能主要与其改善糖异生/糖酵解、氨基酸代谢、脂质代谢、柠檬酸循环和丁酸盐代谢的能力有关。这些结果表明,SQC 通过调节不同途径的 GM 和代谢物可能对 T2DM 发挥有益作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验